During a live global event, Elekta announced the launch of Versa HD™, an advanced linear accelerator system designed to improve patient care and treat a broader spectrum of cancers. Featuring high precision beam shaping and tumor targeting, Versa HD also unveils new capabilities designed to maximize health care system resources and deliver highly sophisticated therapies without compromising treatment times.
To view Multimedia News Release, go to http://www.multivu.com/mnr/60246-elekta-sets-new-benchmark-for-cancer-treatment-launch-of-versa-hd-system
Janssen-Cilag International NV (Janssen) announced today that the European Commission has approved IMBRUVICA™ (ibrutinib) capsules, a first-in-class, once-daily, oral Bruton’s tyrosine kinase (BTK) inhibitor. This new approach to treating blood cancers works by blocking BTK, a protein that helps certain cancer cells live and grow.1 IMBRUVICA is indicated for the treatment of adult patients with relapsed or refractory mantle cell lymphoma (MCL), or adult patients with chronic lymphocytic leukaemia (CLL) who have received at least one prior therapy, or in first line in the presence of 17p deletion or TP53 mutation in patients unsuitable for chemo-immunotherapy.
To view the Multimedia News Release, go to http://www.multivu.com/players/English/72762540-janssen-ec-approval-imbruvica-mcl-cll/
Cycle for Survival, the national movement to beat rare cancers, completed its annual series of rides in March. Indoor cycling instructors from Equinox led rides in 13 cities across the country, with over 21,500 participants at the inspiring, high-energy events.
2015 marked a record-breaking year in fundraising, participants, and supporters. Nine years after the first event, Cycle for Survival is the fastest-growing athletic fundraising event,* and raised $25 million from more than 150,000 supporters.
To view the Multimedia News Release, go to: http://www.multivu.com/players/English/7484551-cycle-for-survival/
Citing projections that by 2030, America’s senior population will reach 20 percent of the population – 78 million people – and new survey information showing that Americans feel increasingly helpless about their personal cancer risk as they grow older, the American Institute for Cancer Research (AICR) today highlighted the emerging research showing that even in later life, many cancers can be delayed or prevented through regular physical activity and a plant-based diet.
To view Multimedia News Release, go to http://multivu.prnewswire.com/mnr/aicr/46620/
On World Cancer Day, new independent evidence confirms that the increasing global trend of unhealthy and sedentary lifestyles is responsible for putting millions at an unnecessarily high risk of cancer.
New estimates released today by the World Cancer Research Fund (WCRF) global network suggest that across a range of countries, making lifestyle changes including maintaining a healthy weight, eating a healthy diet and taking regular physical activity can reduce the risk of common cancers by up to a third.
To view Multimedia News Release, go to http://multivu.prnewswire.com/mnr/prne/worldcancerday/47592/
New findings from the St. Jude Children’s Research Hospital – Washington University Pediatric Cancer Genome Project (PCGP) have helped identify the mechanism that makes the childhood eye tumor retinoblastoma so aggressive. The discovery explains why the tumor develops so rapidly while other cancers can take years or even decades to form.
The finding also led investigators to a new treatment target and possible therapy for the rare childhood tumor of the retina, the light-sensing tissue at the back of the eye. The study appears in the January 11 advance online edition of the scientific journal Nature.
To view Multimedia News Release, go to http://www.multivu.com/mnr/46767-st-jude-genome-project-treatment-childhood-eye-tumor-retinoblastoma
Stiefel, a GSK company, announced today that Hats On For Skin Health, its global campaign with the International League of Dermatological Societies (ILDS), has raised enough funds to produce 15,000 sun-protective hats for albinos living in East Africa and has already distributed more than 2,000 hats. The hats are being distributed from Tanzania, where estimates are that 98 percent of albino children will die before the age of 40 from cancers of the skin – a direct result of the sun’s damaging rays. Worldwide, albinism affects about one in 20,000 people. However the incidence of albinism in Sub-Saharan Africa is significantly higher than in the rest of the world, specifically in Tanzania where the incidence is one in 1,429.
To view Multimedia News Release, go to http://www.multivu.com/mnr/55030-stiefel-gsk-ilds-hats-on-for-skin-health-campaign-east-africa
A pill designed to zero in on abnormal genes that drive specific cancers has produced encouraging early results in children with an uncommon but aggressive type of lymphoma, as well as in children with a rare form of neuroblastoma.
A phase 1 clinical trial of the drug crizotinib achieved remissions, with minimal side effects, for 10 of the children participating in a clinical study carried out by the multicenter Children’s Oncology Group (COG). The results were “an exciting proof-of-principle” for the targeted treatment, said the study leader, Yaël P. Mossé, M.D., a pediatric oncologist at The Children’s Hospital of Philadelphia.
“We are entering a new era of cancer therapy, in which we use knowledge of basic biology to design very specific drugs that target cancer cells with potentially less side effects on healthy tissue,” said Mossé. “In addition, as we concentrate on targets in molecular pathways, we move away from an exclusive focus on one form of cancer to customizing treatments according to biological activity. Abnormal ALK activity occurs in subtypes of neuroblastoma and subtypes of lymphoma, so identifying ALK activity in individual patients may enable us to provide the most effective care.”
To view Multimedia News Release, go to http://www.multivu.com/mnr/50776-childrens-hospital-philadelphia-lymphoma-neuroblastoma-oncology-gene-trial
More than 12,000 cyclers gathered in ten cities across the country in February and early March to raise more than $13.8 million to support rare cancer research at Memorial Sloan-Kettering Cancer Center. The events took place at Equinox clubs in New York City; Los Angeles; San Francisco; Washington, D.C.; Chicago; Greenwich, Connecticut; Miami; Summit, New Jersey; Long Island; and Boston; bringing together a nationwide network of friends, colleagues, caregivers, and cancer survivors to cycle in solidarity in the battle against rare cancers.
To view Multimedia News Release, go to http://www.multivu.com/mnr/60687-memorial-sloan-kettering-cancer-center-cycle-for-survival-event
Nucletron, an Elekta company, and the world leader in brachytherapy, has launched Esteya®, a new approach for treating patients with skin cancer.
Over the last 30 years, more people were diagnosed with skin cancer worldwide than all other cancers combined, making it the most common type of cancer1. This represents a challenge for health care providers in the years to come. With a cure rate of more than 95 percent2, electronic brachytherapy offers a refined treatment modality with excellent cosmesis.
To view Multimedia News Release, go to http://www.multivu.com/mnr/62823-elekta-nucletron-esteya-electronic-brachytherapy-treating-skin-cancer
Phiten, the pioneer of AQUA-METAL™ materials and innovator of metal-infused technology, and professional baseball players C.J. Wilson, Josh Hamilton and J.B. Shuck have teamed up with Be The Match, the nonprofit organization dedicated to helping patients with blood cancers receive life-saving bone marrow and umbilical cord blood transplants. To support Be The Match and raise awareness of the national Be The Match Registry®, Phiten has designed a limited edition Phiten x Be The Match Tornado Necklace with sales benefiting the cause, and the three pro baseball players have been named Ambassadors of Hope by Be The Match.
To view Multimedia News Release, go to http://www.multivu.com/mnr/64376-phiten-and-mlb-players-for-be-the-match-bone-marrow-donor-registry
In recent years there has been a shift in the understanding of cancer. Immunotherapy with vaccines has been emerging as the most promising direction towards a decisive improvement of treatment outcomes.
The Dendritic Cell Vaccine has received FDA approval for prostate cancer and trials are now under way for a variety of other cancers. These vaccines are usually administered on their own.
To view Multimedia News Release, go to http://www.multivu.com/mnr/64654-issels-integrative-immunotherapy-for-standard-therapy-resistant-cancers
